Amgen Inc. vs Gilead Sciences, Inc.

Full side-by-side comparison — 2026

Data as of Aug 14, 2026 · Updated automatically

9
AMGN Wins
0
Tie
10
GILD Wins

AMGN

Price USD 415.21
P/E Ratio 25.5x
Div Yield 0.0236%
Beta 0.41
Sector Health Care

GILD

Price USD 138.36
P/E Ratio 17.7x
Div Yield 0.0233%
Beta 0.34
Sector Health Care

Price Overview

Metric AMGN GILD
Current Price 415.21 138.36
Previous Close 415.21 138.36

Valuation

Metric AMGN GILD
Trailing P/E 25.52 17.70
Forward P/E 17.22 14.01
Price / Book 19.30 14.52
Price / Sales 5.91 5.63
EV / EBITDA 15.57 13.21

Dividends & Income

Metric AMGN GILD
Dividend Yield 0.0236% 0.0233%
Dividend Rate (Annual) 9.80 3.22
5-Year Avg Yield 3.00% 3.96%
Payout Ratio 0.6045% -1.2556%

Risk & Financial Health

Metric AMGN GILD
Beta (Volatility) 0.41 0.34
Debt / Equity 490.28 223.47
Quick Ratio 0.95 0.90
Current Ratio 1.37 1.27

Growth & Profitability

Metric AMGN GILD
Revenue Growth 0.0950% 0.1020%
Earnings Growth 0.6490% 0.5480%
Return on Equity 0.9147% -0.2068%
Revenue / Share 70.68 24.51
Trailing EPS 16.35 -2.66
Forward EPS 24.22 9.87

Analyst Targets

Metric AMGN GILD
Analyst Mean Target 378.31 157.41
Analyst High Target 452.00 180.00
Analyst Low Target 230.00 123.00

Bottom Line: AMGN vs GILD

Gilead Sciences, Inc. (GILD) leads on 10 of 19 comparable metrics.

Gilead Sciences, Inc. is the stronger pick for value investors, while Amgen Inc. may appeal to growth investors.

Gilead Sciences, Inc. has a lower Payout Ratio (-125.56% vs 60.45%), which may suggest the dividend is more sustainable
Amgen Inc. has a higher Return on Equity (91.47% vs -20.68%), which suggests more efficient use of shareholder capital
Amgen Inc. has a higher Trailing EPS (16.35 vs -2.66), which means higher earnings per share over the last 12 months

This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.

AMGN Amgen Inc.

Best for Growth Investors
• Higher Earnings Growth: 64.90%
• Higher Return on Equity: 91.47%
• Higher Forward EPS: 24.22

GILD Gilead Sciences, Inc.

Best for Value Investors
• Lower Trailing P/E: 17.70
• Lower Forward P/E: 14.01
• Lower Price / Book: 14.52
Best for Income Investors
• Higher 5-Year Avg Yield: 3.96%
• Lower Payout Ratio: -125.56%

Watch Out

AMGN carries 490x debt-to-equity — significantly higher than GILD's 223x. High leverage amplifies both gains and losses.

Analyst Upside / Downside

AMGN
-8.9%
GILD
+13.8%

Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.

About These Companies

Amgen Inc. (AMGN)

Health Care · United States · NMS

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS …

View AMGN details →

Gilead Sciences, Inc. (GILD)

Health Care · United States · NMS

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; …

View GILD details →

Frequently Asked Questions

Which has a better dividend yield, AMGN or GILD?
Amgen Inc. currently has the higher dividend yield. Amgen Inc. (AMGN) yields 2.36% while Gilead Sciences, Inc. (GILD) yields 2.33%. Past dividends do not guarantee future payments.
Which is more volatile, AMGN or GILD?
Amgen Inc. is more volatile based on beta. Amgen Inc. has a beta of 0.41 and Gilead Sciences, Inc. has a beta of 0.34. A beta above 1.0 means higher volatility than the overall market.
Which is cheaper by P/E ratio, AMGN or GILD?
Gilead Sciences, Inc. has the lower trailing P/E ratio. Amgen Inc. trades at 25.5x earnings while Gilead Sciences, Inc. trades at 17.7x. A lower P/E may suggest better relative value, but could also reflect lower growth expectations.
Which has more analyst upside, AMGN or GILD?
Based on mean analyst price targets, Gilead Sciences, Inc. has more upside potential. Amgen Inc. has -8.9% upside and Gilead Sciences, Inc. has +13.8% upside from current prices. Analyst estimates are not guaranteed.
Can I track both AMGN and GILD in one portfolio?
Yes. AllInvestView lets you add both Amgen Inc. and Gilead Sciences, Inc. to the same portfolio and monitor price changes, dividends, total return, and allocation — completely free.

Track AMGN and GILD in Your Portfolio

Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.

Start Free Portfolio

Health Care Peers

Stock Pages

Screen, define and plan around these two stocks.

Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Lowest P/E stocks Value screen ranked by earnings multiple. Investing glossary Understand every metric in the table. Capital gains tax calculator Plan the tax before you sell. Portfolio templates Ready-made allocation models to copy.